Latest Breaking News On - More doses - Page 5 : comparemela.com

Pharma Stock Roundup: JNJ s Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates Zacks.com 2 hrs ago J&J JNJ announced strong first-quarter results, beating estimates for both earnings and sales. Roche’s RHHBY COVID-19 diagnostics tests sales boosted the top line, offsetting declines in its core drug business. The FDA granted approval to Glaxo’s GSK endometrial cancer therapy, Jemperli (dostarlimab). Recap of the Week’s Most Important Stories J&J Earnings & Sales Beat: J&J beat first-quarter estimates for earnings as well as sales. Its Pharmaceuticals unit continued to perform above market levels while the recovery in the Medical Devices unit continued. However, unfavorable comparisons to the year-ago quarter due to COVID-19 pantry loading and demand surges experienced in 2020 hurt sales of the Consumer Health segment in the first quarter of 2021

United statesSanofi sarclisaMabthera rituxanAmgen kyprolisPharmacovigilance risk assessment committeeUs centers for diseaseIts pharmaceuticalsLarge cap pharmaceuticals industryEuropean commissionDrug developmentEuropean unionEuropean medicines agencyConsumer healthMost importantSales beatMedical devices